-
Mashup Score: 5
Recent research has shown encouraging results for older patients with classical Hodgkin lymphoma treated with Adcetris plus chemotherapy or Opdivo.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 1Big Data and Collaboration: A Case Study on Improving Outcomes in Hodgkin Lymphoma | Docwire News - 2 month(s) ago
Dr. Chadi Nabhan is joined by esteemed guests from the HoLISTIC consortium to discuss Hodgkin lymphoma.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
@chadinabhan is joined by esteemed guests from the HoLISTIC consortium to discuss #Hodgkinlymphoma. Listen Now: https://t.co/4E2rwxA9ry https://t.co/ktSDOjyxNU
-
-
Mashup Score: 2The Latest in Hodgkin Treatments 2024: Patient Event Registration - 2 month(s) ago
Join Hodgkin lymphoma experts discussing the latest treatments, symptom relief, personalized care, sequencing, better monitoring, and hope.
Source: thepatientstory.comCategories: General Medicine News, Partners & KOLsTweet-
COMING UP! We’ve got the latest treatment options for #HodgkinLymphoma in 2024! 🩸 🗓️ February 21 ⏰ 6 PM EST Join us with the @Patient_Story to talk with @NatalieGroverMD from @UNC_SOM and Dr. Stephen Ansell from @MayoClinic. Register today 👉 https://t.co/UP1dI5WcPR
-
-
Mashup Score: 8
Mazyar Shadman, MD, MPH, and the Oncology Brothers discuss recent data from SWOG S1826 on nivolumab-AVD in patients aged 60 years and older with advanced stage Hodgkin lymphoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
SWOG S1826: Nivolumab-AVD in Older Patients with Advanced #Hodgkin #Lymphoma https://t.co/Q36FxyHkQB via @targetedonc
-
-
Mashup Score: 8
Mazyar Shadman, MD, MPH, and the Oncology Brothers discuss recent data from SWOG S1826 on nivolumab-AVD in patients aged 60 years and older with advanced stage Hodgkin lymphoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
SWOG S1826: Nivolumab-AVD in Older Patients with Advanced #Hodgkin #Lymphoma https://t.co/Q36FxyHkQB via @targetedonc
-
-
Mashup Score: 2Hodgkin Lymphoma - Cancer Stat Facts - 5 month(s) ago
Hodgkin Lymphoma statistics
Source: seer.cancer.govCategories: General Medicine News, Onc News and JournalsTweet-
#HodgkinLymphoma is most frequently diagnosed among people between 20-34 years. The median age of diagnosis is 39. Visit our Cancer Stat Facts sheet to learn more: https://t.co/9L6h7VgNUG https://t.co/UbrPfontiE
-
-
Mashup Score: 4Hodgkin Lymphoma - Mitigating Toxicity While Preserving Cure - Eight Year Data from MIOT International, Chennai, India - 5 month(s) ago
BackgroundOne of the most treatable cancers, Hodgkin’s lymphoma (HL), has a 5-year survival rate of approximately 85%.We still see relapse and refract…
Source: www.sciencedirect.comCategories: General Medicine News, Hematologists1Tweet-
Hodgkin Lymphoma - Mitigating Toxicity While Preserving Cure - Y https://t.co/WJzhAmwcuc Our Eight-year data reveals a 93% 3-year EFS for early and 81% for advanced-stage, aligning with West.Consider Allo in 3rd line. Brentuximab, shows promise. #HodgkinLymphoma @HCC_HemeCancer
-
-
Mashup Score: 0Relapse Refractory Hodgkin lymphoma [slides 2023] - 7 month(s) ago
By: Allen Wilbanks Date: September 27/2023 Swetha Kambhampati, MD, presented at a conference with gratitude to the organizers and Dr. Flowers for the opportunity. She discussed innovative approaches for relapse refractory Hodgkin lymphoma. Dr. Kambhampati outlined her talk, covering BV and PD-1 inhibitors as salvage…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🩺 Swetha Kambhampati, MD, delivered an enlightening talk at the conference today, shedding light on cutting-edge approaches for relapse refractory #HodgkinLymphoma 👥 @_MDEducation @Ryan_Fitzpatric @cityofhope [video]: https://t.co/uMp0SaXbx7 https://t.co/mkW2wfBoUA
-
🩺 Swetha Kambhampati, MD, delivered an enlightening talk at the conference today, shedding light on cutting-edge approaches for relapse refractory #HodgkinLymphoma 👥 @_MDEducation @Ryan_Fitzpatric @cityofhope [video]: https://t.co/uMp0SaXbx7 https://t.co/z5GHw4J3Ge
-
-
Mashup Score: 0
Nivolumab plus brentuximab vedotin, followed by ISRT, appears safe and effective for low-risk, relapsed classical Hodgkin lymphoma.
Source: www.cancertherapyadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nivolumab and brentuximab vedotin, followed by consolidative ISRT, is a safe and effective treatment option for young patients with low-risk, relapsed classical #HodgkinLymphoma. Presented by @_ShankarSiva at @ASTRO_org #ASTRO23. https://t.co/5RNI2O6wHY
-
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
After a median 1-year follow-up of Stage III or IV classical #Hodgkinlymphoma, progression-free survival with nivolumab plus #chemotherapy was 94% versus 86% for the brentuximab plus chemotherapy. https://t.co/0XtFxkkykP https://t.co/4xn9Vhh8Wk
-
Treatment with Adcetris plus chemotherapy or Opdivo was demonstrated as a “promising” option for patients with classical #HodgkinLymphoma, according to Dr. Jonathan W. Friedberg (@DrJFriedberg) of @WilmotCancer and @UR_Med. Read more: https://t.co/RfNCCVAKL1